BridgeBio Pharma (2CL) Q1 2024 Earnings Report
DE:2CL Q1 2024 EPS Results
- Actual EPS
- -EUR 0.18
- Consensus EPS
- -EUR 0.66
- Beat/Miss
- Beat by +EUR 0.48
- One Year Ago EPS
- -EUR 0.82
DE:2CL Q1 2024 Revenue Results
- Actual Revenue
- EUR 188.76M
- Expected Revenue
- EUR 6.49M
- Beat/Miss
- Beat by +EUR 182.27M
- YoY Revenue Growth
- +11461.88%
Earnings Announcement Details
- Quarter
- Q1 2024
- Date
- 05/02/2024
- Time
- Before Open
- Conference Call
- Thursday, May 2, 2024
DE:2CL Upcoming Earnings
BridgeBio Pharma's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q1 2024 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q1 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2024 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:2CL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.53- | -0.89 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.48-0.38 | -0.85 | 55.79% (+0.47) | |
| Aug 10, 2026 | 2026 (Q2) | -0.52-0.70 | -0.85 | 17.89% (+0.15) | |
| May 07, 2026 | 2026 (Q1) | -0.61-0.75 | -0.79 | 4.55% (+0.04) | |
| Feb 24, 2026 | 2025 (Q4) | -0.64-0.89 | -1.25 | 28.57% (+0.36) | |
| Oct 29, 2025 | 2025 (Q3) | -0.80-0.85 | -0.77 | -10.47% (-0.08) | |
| Aug 05, 2025 | 2025 (Q2) | -0.71-0.85 | -0.35 | -143.59% (-0.50) | |
| Apr 29, 2025 | 2025 (Q1) | -0.82-0.79 | -0.18 | -340.00% (-0.61) | |
| Feb 20, 2025 | 2024 (Q4) | -1.00-1.25 | -0.86 | -45.83% (-0.39) | |
| Nov 12, 2024 | 2024 (Q3) | -0.90-0.77 | -0.97 | 20.37% (+0.20) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
